CoChat

Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer

Kawakami, Hisato, Huang, Shengbing, Pal, Krishnendu, Dutta, Shamit K., Mukhopadhyay, Debabrata, Sinicrope, Frank A. · 2016 · Molecular Cancer Therapeutics
Cited by 41

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Oncogenic BRAFV600E mutations activate MAPK signaling and are associated with treatment resistance and poor prognosis in patients with colorectal cancer. In BRAFV600E-mutant colorectal cancers, treatment failure may be related to BRAFV600E-mediated apoptosis resistance that occurs by an as yet undefined mechanism. We found that BRAFV600E can upregulate anti-apoptotic MCL-1 in a gene dose-dependent manner using colorectal cancer cell lines isogenic for BRAF. BRAFV600E-induced MCL-1 upregulation was confirmed by ectopic BRAFV600E expression that activated MEK/ERK signaling to phosphorylate (MCL-1Thr163) and stabilize MCL-1. Upregulation of MCL-1 was mediated by MEK/ERK shown by the ability of ERK siRNA to suppress MCL-1. Stabilization of MCL-1 by phosphorylation was shown by a phosphorylation-mimicking mutant and an unphosphorylated MCL-1 mutant that decreased or increased MCL-1 protein turnover, respectively. MEK/ERK inhibition by cobimetinib suppressed MCL-1 expression/phosphorylation and induced proapoptotic BIM to a greater extent than did vemurafenib in BRAFV600E cell lines. MCL-1 knockdown versus control shRNA significantly enhanced cobimetinib-induced apoptosis in vitro and in HT29 colon cancer xenografts. The small-molecule MCL-1 inhibitor, A-1210477, also enhanced cobimetinib-induced apoptosis in vitro that was due to disruption of the interaction of MCL-1 with proapoptotic BAK and BIM. Knockdown of BIM attenuated BAX, but not BAK, activation by cobimetinib plus A-1210477. In summary, BRAFV600E-mediated MEK/ERK activation can upregulate MCL-1 by phosphorylation/stabilization to confer apoptosis resistance that can be reversed by MCL-1 antagonism combined with cobimetinib, suggesting a novel therapeutic strategy against BRAFV600E-mutant CRCs. Mol Cancer Ther; 15(12); 3015–27. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-16-0017

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 43

  1. Hatzivassiliou, 2013, Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers, Nature, 501, 232, 10.1038/nature12441 · DOI · Paper page
  2. Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
  3. Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 · DOI · Paper page
  4. Farina-Sarasqueta, 2010, The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients, Ann Oncol, 21, 2396, 10.1093/annonc/mdq258 · DOI · Paper page
  5. Ogino, 2012, Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803, Clin Cancer Res, 18, 890, 10.1158/1078-0432.CCR-11-2246 · DOI · Paper page
  6. Sinicrope, 2015, Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes, Gastroenterology, 148, 88, 10.1053/j.gastro.2014.09.041 · DOI · Paper page
  7. Phipps, 2015, Association between molecular subtypes of colorectal cancer and patient survival, Gastroenterology, 148, 77, 10.1053/j.gastro.2014.09.038 · DOI · Paper page
  8. Tie, 2011, Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation, Int J Cancer, 128, 2075, 10.1002/ijc.25555 · DOI · Paper page
  9. Tran, 2011, Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer, Cancer, 117, 4623, 10.1002/cncr.26086 · DOI · Paper page
  10. Wilcox, 2015, Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147), J Clin Oncol 33, 10.1200/jco.2015.33.15_suppl.3590 · doi:10.1200/jco.2015.33.15_suppl.3590
  11. Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782 · DOI · Paper page
  12. Larkin, 2014, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, N Engl J Med, 371, 1867, 10.1056/NEJMoa1408868 · DOI · Paper page
  13. Cartlidge, 2008, Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival, Pigment Cell Melanoma Res, 21, 534, 10.1111/j.1755-148X.2008.00491.x · DOI · Paper page
  14. Jiang, 2008, Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress, Cancer Res, 68, 6708, 10.1158/0008-5472.CAN-08-0349 · DOI · Paper page
  15. Boisvert-Adamo, 2008, Mutant B-RAF mediates resistance to anoikis via Bad and Bim, Oncogene, 27, 3301, 10.1038/sj.onc.1211003 · DOI
  16. Zhang, 2013, Role of apoptosis in colon cancer biology, therapy, and prevention, Curr Colorectal Cancer Rep, 9, 1, 10.1007/s11888-013-0188-z · DOI
  17. Masuoka, 2010, Clinical relevance of apoptotic regulatory proteins in colorectal cancers, Curr Colorectal Cancer Rep, 6, 111, 10.1007/s11888-010-0051-4 · DOI
  18. Ley, 2005, Regulatory phosphorylation of Bim: sorting out the ERK from the JNK, Cell Death Differ, 12, 1008, 10.1038/sj.cdd.4401688 · DOI · Paper page
  19. Lucas, 2012, Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737, Clin Cancer Res, 18, 783, 10.1158/1078-0432.CCR-11-1166 · DOI
  20. Frederick, 2014, Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics, PLoS One, 9, e101286, 10.1371/journal.pone.0101286 · DOI · Paper page
  21. Akgul, 2009, Mcl-1 is a potential therapeutic target in multiple types of cancer, Cell Mol Life Sci, 66, 1326, 10.1007/s00018-008-8637-6 · DOI · Paper page
  22. Huang, 2008, BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells, Cancer Res, 68, 2944, 10.1158/0008-5472.CAN-07-2508 · DOI · Paper page
  23. Huang, 2009, BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells, Clin Cancer Res, 15, 150, 10.1158/1078-0432.CCR-08-1575 · DOI
  24. Ding, 2008, Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer, Cancer Res, 68, 6109, 10.1158/0008-5472.CAN-08-0579 · DOI · Paper page
  25. Phillips, 2015, Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199), Blood Cancer J, 5, e368, 10.1038/bcj.2015.88 · DOI
  26. Xiao, 2015, MCL-1 Is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor, Mol Cancer Ther, 14, 1837, 10.1158/1535-7163.MCT-14-0928 · DOI · Paper page
  27. Rizos, 2014, BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact, Clin Cancer Res, 20, 1965, 10.1158/1078-0432.CCR-13-3122 · DOI · Paper page
  28. Van Allen, 2014, The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma, Cancer Discov, 4, 94, 10.1158/2159-8290.CD-13-0617 · DOI · Paper page
  29. Nazarian, 2010, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, 468, 973, 10.1038/nature09626 · DOI · Paper page
  30. Welcker, 2004, The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation, Proc Natl Acad Sci U S A, 101, 9085, 10.1073/pnas.0402770101 · DOI · Paper page
  31. Yada, 2004, Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7, EMBO J, 23, 2116, 10.1038/sj.emboj.7600217 · DOI · Paper page
  32. Lin, 2002, Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase, EMBO J, 21, 4037, 10.1093/emboj/cdf406 · DOI · Paper page
  33. Ju, 2007, Ubiquitin-mediated degradation of Rpn4 is controlled by a phosphorylation-dependent ubiquitylation signal, Biochim Biophys Acta, 1773, 1672, 10.1016/j.bbamcr.2007.04.012 · DOI
  34. Becker, 2014, Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor, Oncogene, 33, 1158, 10.1038/onc.2013.45 · DOI
  35. Wang, 2007, Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1, Clin Cancer Res, 13, 4934, 10.1158/1078-0432.CCR-07-0665 · DOI · Paper page
  36. Fofaria, 2015, Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma, Oncotarget, 6, 40535, 10.18632/oncotarget.5755 · DOI · Paper page
  37. Morales, 2011, Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells, Blood, 118, 1329, 10.1182/blood-2011-01-327197 · DOI · Paper page
  38. Bhalla, 2011, The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma, Blood, 118, 1052, 10.1182/blood-2011-03-340109 · DOI
  39. O'Reilly, 2009, MEK/ERK-mediated phosphorylation of Bim is required to ensure survival of T and B lymphocytes during mitogenic stimulation, J Immunol, 183, 261, 10.4049/jimmunol.0803853 · DOI · Paper page
  40. Wiggins, 2010, Refining the minimal sequence required for ERK1/2-dependent poly-ubiquitination and proteasome-dependent turnover of BIM, Cell Signal, 22, 801, 10.1016/j.cellsig.2010.01.004 · DOI
  41. Nguyen, 2013, When ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling, Cell Commun Signal, 11, 52, 10.1186/1478-811X-11-52 · DOI · Paper page
  42. Sarosiek, 2013, BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response, Mol Cell, 51, 751, 10.1016/j.molcel.2013.08.048 · DOI · Paper page
  43. Bendell, 2016, Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC), J Clin Oncol 34, 10.1200/JCO.2016.34.15_suppl.3502 · DOI · Paper page

Cited by

See all 41

Metadata

Authors
Kawakami, H., Huang, S., Pal, K., Dutta, S. K., Mukhopadhyay, D., & Sinicrope, F. A.
Venue
Molecular Cancer Therapeutics
Published
2016-12-01
Volume
15
Issue
12
Pages
3015-3027
ISSN
  • 1535-7163
  • 1538-8514
Cited by
41
References
13
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0017
The paper
Kawakami, H., Huang, S., Pal, K., Dutta, S. K., Mukhopadhyay, D., & Sinicrope, F. A. (2016). Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.